Good morning, all. Damian Garde here filling in for Ed Silverman on the final day of a month that, while numerically quite short, has somehow felt metaphysically interminable. Here as always is a smattering of items to help you set off on another workday of meetings, deadlines, and debating the etiquette of leaving your camera off. May it be painless, and, as always, if you hear anything interesting, do let us know.
The high-ranking Food and Drug Administration official behind the polarizing approval of Aduhelm is leaving the agency, STAT reports. Billy Dunn, who led the FDA’s neuroscience department, is leaving to “explore other opportunities,” according to an internal FDA email sent Monday. Once a behind-the-scenes bureaucrat, Dunn became the center of a damaging FDA scandal in 2021 when the agency overruled its advisers to approve Aduhelm, the Biogen-developed Alzheimer’s treatment.
An Indian court sentenced two pharmaceutical executives to prison for exporting shoddy medicines, Reuters tells us. The founder and technical director of Maiden Medicines face 30 months in prison for their roles in shipping heartburn medicines “not of standard quality” to Vietnam, a court ruled. Maiden has faced escalating legal scrutiny since last year, when the World Health Organization linked the company’s cough syrups to the deaths of children in Gambia.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect